Dr Reddys Laboratories (RDY) Cost of Revenue (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported Cost of Revenue for 15 consecutive years, with $342.0 million the latest figure, recorded in Q2 2023.

• Quarterly Cost of Revenue changed N/A year-over-year to $342.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $336001.0 billion (changed N/A YoY) and the FY2026 annual result came in at $1.7 billion, up 6.96% from the prior year.
• Cost of Revenue grew to $342.0 million in Q2 2023 per RDY's latest filing, from $335.0 million in the prior quarter.
• Over the last five years, Cost of Revenue for RDY reached as high as $336000.0 billion in Q3 2022 and fell as low as $263.0 million in Q1 2019.
• A 5-year average of $28000.3 billion and a median of $314.5 million in 2020 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2019 — Cost of Revenue grew 21.7% — and 2020, when it climbed 0.38%.
• Year by year, Cost of Revenue stood at $282.0 million in 2019, then rose by 10.64% to $312.0 million in 2020, then increased by 16.03% to $362.0 million in 2021, then retreated by 9.12% to $329.0 million in 2022, then grew by 3.95% to $342.0 million in 2023.
• According to Business Quant data, Cost of Revenue over the past three periods registered $342.0 million, $335.0 million, and $329.0 million for Q2 2023, Q1 2023, and Q4 2022 respectively.